SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced that the first patient has been dosed at University of Pittsburgh Medical Center (UPMC) in its Phase 1 clinical trial ...
OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback